Investor Presentaiton
r
R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAS
Product Type & Introduction
✓
Henlius pipeline contains 59 molecules and 18 R&D platforms with 48 innovative drugs and 11
biosimilars
Pipeline focuses around oncology while starting to explore new TAs including Autoimmune /
Ophthalmology / Metabolic / Rare Disease...
69%
31%
壽
Solid Tumor
Oncology
•
Breast Cancer
•
Lung Cancer
MSI-H Solid Tumor
Gastric Cancer
•
CRC
ESCC
HNSCC
•
NPS
•
NSCC
HCC
Non-oncology
•
IBD
•
SLE
Autoimmune
•
PBC/PSC
•
RA
DKD
Metabolic
.
18
35
Pipeline Distribution by Stage
R&D
Platform
Discovery
4
7
4
IND
4
LO
Phase I
5
Phase II
Phase III
Marketed
NAFLD/NASH
Modality Distribution (1)
Cyclic Peptides mRNA
Fusion Protein
3%
9% 3%
Ophthalmology
.
Wet AMD
Cardiova
scular
Heart Failure
HLP
SMC 16%
CNS
.
ALS/PD
Non-Hodgkin Lymphoma
Chronic Lymphocytic
LCH/ECD
Leukemia
Hematology
Rare
Diseases
•
IPF
Multiple Myeloma
•
ALS
(1) SMC: Small molecule conjugates; AXC: Antibody X conjugates, including AEC, AOC & ADC
7
O 2024 Henlius.
mAb
43%
26%
AxC
A Henlius 复宏汉霖View entire presentation